|Other names: MYH-associated polyposis|
|MUTYH-associated polyposis (MAP) -Diffuse localization of wild-type MUTYH protein in colonic epithelial cells, as evidenced with specific antibodies|
|Specialty||Medical genetics, gastroenterology|
|Causes||DNA repair gene mutation|
|Differential diagnosis||Familial adenomatous polyposis, Lynch syndrome|
MUTYH-associated polyposis (also known as MYH-associated polyposis) is an autosomal recessive polyposis syndrome. The disorder is caused by mutations in both alleles (genetic copies) of the DNA repair gene, MUTYH. The MUTYH gene encodes a base excision repair protein, which corrects oxidative damage to DNA. Affected individuals have an increased risk of colorectal cancer, precancerous colon polyps (adenomas) and an increased risk of several additional cancers. About 1–2 percent of the population possess a mutated copy of the MUTYH gene, and less than 1 percent of people have the MUTYH associated polyposis syndrome. The presence of 10 or more colon adenomas should prompt consideration of MUTYH-associated polyposis, familial adenomatous polyposis and similar syndromes.
Signs and symptoms
The clinical presentation of MUTYH-associated polyposis would be consistent with colorectal polyps
MUTYH-associated polyposis is caused by a mutation of the MUTYH gene, which is located on chromosome 1. The condition may be caused by identical mutations affecting both copies of the gene (biallelic mutations) or where each allele is affected by different mutations (compound heterozygote).
The evaluation of MUTYH-associated polyposis can be ascertained via molecular genetic test
Treatment is similar to familial adenomatous polyposis, which varies based on the extent of polyps.
All first degree relatives of individuals with the condition should undergo screening for MUTYH associated polyposis. To identify risk for future offspring, screening should be offered to spouses of individuals affected by MUTYH associated polyposis. If the spouse is a carrier of a mutation in MUTYH, then genetic counseling should be offered to the children as they approach adulthood.
Without surveillance or screening, between 43% and 100% of individuals with MUTYH-associated polyposis develop colorectal cancer.
- ↑ Tomlinson, Ian (April 2015). "An update on the molecular pathology of the intestinal polyposis syndromes". Diagnostic Histopathology. 21 (4): 147–151. doi:10.1016/j.mpdhp.2015.04.006.
- ↑ Gupta, S; Provenzale, D; Llor, X; Halverson, AL; Grady, W; Chung, DC; Haraldsdottir, S; Markowitz, AJ; Slavin TP, Jr; Hampel, H; CGC.; Ness, RM; Weiss, JM; Ahnen, DJ; Chen, LM; Cooper, G; Early, DS; Giardiello, FM; Hall, MJ; Hamilton, SR; Kanth, P; Klapman, JB; Lazenby, AJ; Lynch, PM; Mayer, RJ; Mikkelson, J; CGC.; Peter, S; Regenbogen, SE; Dwyer, MA; CGC.; Ogba, N (1 September 2019). "NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2019". Journal of the National Comprehensive Cancer Network. 17 (9): 1032–1041. doi:10.6004/jnccn.2019.0044. PMID 31487681.
- ↑ "MYH-associated polyposis - About the Disease - Genetic and Rare Diseases Information Center". rarediseases.info.nih.gov. Archived from the original on 21 April 2022. Retrieved 27 September 2022.
- ↑ 4.0 4.1 4.2 4.3 Patel, R; Hyer, W (October 2019). "Practical management of polyposis syndromes". Frontline Gastroenterology. 10 (4): 379–387. doi:10.1136/flgastro-2018-101053. PMC 6788137. PMID 31656563.
- ↑ 5.0 5.1 Nielsen, Maartje; Infante, Elena; Brand, Randall (1993). "MUTYH Polyposis". GeneReviews®. University of Washington, Seattle. Archived from the original on 21 September 2022. Retrieved 27 September 2022.